The use of adjunctive CT bone reading software in women with breast cancer detected between 8 to 22 percent more metastatic lesions for reviewing radiologists and reduced CT interpretation time by 50 percent or more, according to a new study.
|Articles|December 3, 2008
GE presents newly approved molecular agent
Author(s)Greg Freiherr
GE Healthcare debuted at RSNA 2008 a recently FDA-approved molecular imaging agent that homes in on rare neuroendocrine tumors. The new agent, technically known as Iobenguane I 123 Injection, was approved earlier this year for use in diagnosis and during follow-up of patients with these tumors, if relapse or recurrence is suspected, according to GE, which began shipping the product in late October.
Advertisement
GE Healthcare debuted at RSNA 2008 a recently FDA-approved molecular imaging agent that homes in on rare neuroendocrine tumors. The new agent, technically known as Iobenguane I 123 Injection, was approved earlier this year for use in diagnosis and during follow-up of patients with these tumors, if relapse or recurrence is suspected, according to GE, which began shipping the product in late October.
The agent promises to have a major impact on the diagnosis of children with neuroblastoma, the most common extracranial solid tumor of young children up to five years of age. It will also provide reliable imaging data to aid in identifying primary and metastatic pheochromocytoma, a predominantly adult tumor that often presents diagnostic challenges. These two diseases can be difficult to detect at an early stage because symptoms may be nonspecific when the tumors are small.
GE Healthcare began developing AdreView in 2004. It was granted orphan drug status by the FDA in December 2006. In May 2008, AdreView received priority review status from the FDA.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
SubscribeAdvertisement
Related to this article
Expert Radiology is a **radiologist-run teleradiology practice with 10 years of experience**, hiring teleradiologists earning **$500–$900/hr with per-dictation pay**. Work from anywhere with true flexibility, **no shifts, no call, and no weekends**.
Our case mix is **predominantly outpatient and noncontrast**, with approximately **75% MRI**, plus X-ray and CT.
We cover **malpractice with tail**, handle all medical licensing, and ship you a **$10K reading station with six vertical 4K monitors**.
Minimum commitment is an **average of 400 cases per month**.
**Book a call with Brandi Escapule, Principal, Physician Services.**
How will generative AI software be evaluated by the FDA in the future? What’s next for point-of-care ultrasound? What steps have been successful in facilitating adoption of AI applications across enterprise systems? Leaders in radiology and health care will be discussing these topics and more at the upcoming HLTH USA conference.
While the allure of partnership or a hierarchical promotion system for those who paid their dues once sounded promising, the current reality amid declining reimbursements, thinning practice margins and private equity acquisitions is going after the gig with the most optimal lifestyle and paycheck.
Catch up on the top radiology content of the past week.
In the third of a three-part podcast episode, Wendie Berg, MD, PhD, FACR, FSBI, Manisha Bahl, MD, and Amy Patel, MD discuss recent developments with autonomous AI in breast imaging and share their perspective on the overall potential of AI to help mitigate the radiologist shortage.
In a recent interview, Amir Iravani, MD, FRACP, discussed the radiotherapeutic agent 177Lu-edotreotide and new dosimetry data from the COMPETE trial that was recently presented at the ASTRO conference.
While AI offers the lure of efficiency and cleaner writing in scientific research, maintaining the principles of authorship and intellectual engagement is perhaps more important than ever before.
Advertisement
Advertisement